Abstract
Hematopoietic stem cell transplantation（HSCT）, a curative procedure for the majority of hematologic disorders, has seen remarkable development in China. In 1964, Lu Daopei performed Asia's first and the world's fourth HSCT, marking the beginning of China's progress in this field. Huang Xiaojun completed the world's first haploidentical HSCT without in vitro T-cell depletion in 2000. The protocol has evolved into a system named “Beijing Protocol” by the Worldwide Network for Blood and Marrow Transplantation（WBMT）in 2016, which is currently a mainstream global haploidentical transplantation protocol. The emergence of novel cellular therapies has revolutionized the conventional hematopoietic stem cell transplantation model. From learning from the west, Chinese scholars have strived to reshape the global HSCT landscape.